UTHR's Quality Score fell 1 point on Fri, Nov 6, to 12. Its price fell below its average of the last 21 days (2 chart checks stopped).
Follow UTHR's trial news. Pro members can get an alert when United Therapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Down 1% on Oct 14.
Up 178% over the five years to Nov 6 while the S&P 500 rose 68%; down 1% on Oct 14.
6 reasons, from its filings, with the timeline and its peers, for Pro members.
| The chart | Above a rising 200-day average |
| Latest filing | 8-K, Nov 4 |
United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization
UTHR closed +3.8% that day.
After its last 4 reports it closed +4.6% on average, higher 4 of 4 times.
No shelf registration or at-the-market program on file in the last three years.
CEO Martine A. Rothblatt sold 1,960 shares on Nov 5, under a planned sale. 256 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Above Averagefor quality, not price, 3 of 14 chart checks firingWhat the Quality Score means
UTHR is #36 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 36 |
Share count against a year before: UTHR -2.5%, LQDA +3.9%.
Expected to report Wed Feb 24, before the open (in 107 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $832.5M, 4% more than a year ago; a profit of $5.71 a share, from $7.16.
“Total Tyvaso revenues increased by five percent to $503.8 million in the third quarter of 2026, as compared to $478.0 million in the third quarter of 2025, driven by growth in Tyvaso DPI revenues, partially offset by a decrease in Nebulized Tyvaso revenues.”
| Line | Q3 2026 | Q2 2026 | Q3 2025 |
|---|---|---|---|
| Tyvaso | $504M | $453M | $478M |
Each quarter's sales and their share of its total. Figures as filed (SEC filing, Nov 4)
No outlook figures read from this release.
“Our ETR for the three months ended September 30, 2026 increased compared to our ETR for the three months ended September 30, 2025, primarily due to nondeductible IPR&D expense related to the acquisition of Thymmune, which was capitalized for tax purposes into the basis of the stock acquired.”
From its results filing (SEC filing · Nov 4)
Sales grew 17% a year over 5 years, fiscal 2020 to 2025.
Its share count grew 1.4% a year over 5 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 4, 2026 | -2.9% | +1.2% | not yet |
| Aug 5, 2026 | -2.6% | +0.1% | -0.6% |
| May 6, 2026 | +3.0% | +4.3% | +1.7% |
Sales grew in six of the last seven years, to $3.2B in 2025. It made a profit in each of the five years.
RSI 48.9, MACD below signal, above both averages. Not scored.
One insider bought $864K across 1 filing, and one insider sold $115K across 2 filings, in the last 6 months. The newest:
One trade disclosed in the last six months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: UTHR is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
“For the treatment of PAH, we compete with many approved products in the United States and the rest of the world.”
UTHR scores 12 today, which Breakaway calls Above Average. It is #36 of 281 in Biotech by Quality Score, with 3 of 14 chart checks firing. Down 1% on Oct 14. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
UTHR scores 12 today, which Breakaway calls Above Average (11 to 14). That is #36 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind UTHR's 12.
One insider bought $864K across 1 filing, and one insider sold $115K across 2 filings, in the last 6 months. The newest is Nilda Mesa, Director, who sold $66K on Sep 14. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.